Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments (2010 - 2026)

Nektar Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $101.5 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 46.4% year-over-year to $101.5 million; the TTM figure through Mar 2026 stood at $316.8 million (up 11.09% YoY), while the FY2025 annual figure was $284.7 million, down 16.36% from the prior year.
• Change in Acquisitions & Divestments was $101.5 million for Q1 2026 at Nektar Therapeutics, up from $92.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $238.4 million in Q2 2022 to a low of -$626.4 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $42.7 million across 5 years, with a median of $92.0 million in 2025.
• Biggest YoY gain for Change in Acquisitions & Divestments was 23845000.0% in 2022; the steepest drop was 82.18% in 2022.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at -$626.4 million in 2022, then advanced by 21.08% to -$494.4 million in 2023, then jumped by 113.17% to $65.1 million in 2024, then jumped by 41.28% to $92.0 million in 2025, then gained by 10.32% to $101.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $101.5 million (Q1 2026), $92.0 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.